805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes
Background: The relationship of sarcopenia with relevant features of T2D and its treatment are inconsistent in the literature. Aims: To evaluate the prevalence of sarcopenia in insulin treated older adults with T2DM. Methods: This is a cross sectional data from a prospective observational cohort stu...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 71 |
| creator | LEITE, SILMARA A.O. BASTOS, MURILO SILVA, MICHAEL LAVALLE, ANA C.R. BERTOGY, MARIA C. VIEIRA, SUELEN C. UMPIERREZ, GUILLERMO E. |
| description | Background: The relationship of sarcopenia with relevant features of T2D and its treatment are inconsistent in the literature.
Aims: To evaluate the prevalence of sarcopenia in insulin treated older adults with T2DM.
Methods: This is a cross sectional data from a prospective observational cohort study that evaluated subjects older than 65 y/o with T2D on insulin therapy, with or without oral agents, and HbA1c between 7% and 9%, identified from a public hospital and a private diabetes clinic and invited by phone to participate (n= 462) . Patients treated with GLP1 agonists; eGFR 4. Muscle strength was assessed by handgrip strength (HS) using a manual dynamometer (Jamar®) . The muscle mass was assessed by electrical bioimpedance (BIA - Inbody®) obtaining the skeletal muscle mass index (SMI = MM appendicular / height2) . The physical performance was assessed by the timed up-and-go test (TUG) . The presence of sarcopenia was considered when HS |
| doi_str_mv | 10.2337/db22-805-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2685594640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2685594640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c630-a10edd2bef8d27d64adfe3ea661921f954cfd8762929146fca72633db253ed173</originalsourceid><addsrcrecordid>eNotkEtLxDAUhYMoOI5u_AUBd0I0jzZp3A3ja2BwCnbhLmSaG-xQ25qkyPx7O47cxdl8nMP9ELpm9I4Loe7dlnNS0JyUJ2jGtNBEcPVximaUMk6Y0uocXcS4o5TK6Wbo7Q9-wO821P0AXWNx0-FVF8e26UgVwCZweNM6CHjhxjbh0qYGuhTxT5M-cbUfAHP82NgtJIiX6MzbNsLVf85R9fxULV_JevOyWi7WpJaCEssoOMe34AvHlZOZdR4EWCmZ5szrPKu9K5TkmmuWSV9bxaUQ03O5AMeUmKObY-0Q-u8RYjK7fgzdtGi4LPJcZzKjE3V7pOrQxxjAmyE0XzbsDaPmoMscdJnJgCnFLzjBW3I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685594640</pqid></control><display><type>article</type><title>805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>LEITE, SILMARA A.O. ; BASTOS, MURILO ; SILVA, MICHAEL ; LAVALLE, ANA C.R. ; BERTOGY, MARIA C. ; VIEIRA, SUELEN C. ; UMPIERREZ, GUILLERMO E.</creator><creatorcontrib>LEITE, SILMARA A.O. ; BASTOS, MURILO ; SILVA, MICHAEL ; LAVALLE, ANA C.R. ; BERTOGY, MARIA C. ; VIEIRA, SUELEN C. ; UMPIERREZ, GUILLERMO E.</creatorcontrib><description>Background: The relationship of sarcopenia with relevant features of T2D and its treatment are inconsistent in the literature.
Aims: To evaluate the prevalence of sarcopenia in insulin treated older adults with T2DM.
Methods: This is a cross sectional data from a prospective observational cohort study that evaluated subjects older than 65 y/o with T2D on insulin therapy, with or without oral agents, and HbA1c between 7% and 9%, identified from a public hospital and a private diabetes clinic and invited by phone to participate (n= 462) . Patients treated with GLP1 agonists; eGFR <30 ml/min; Hb <11g/dL; ALT> 3x ULN; glucocorticoid use in the previous 3 months, and active malignancy were excluded. The diagnosis of sarcopenia was based on the European Working Group on Sarcopenia in Older People (EWGSOP2) . The SARC-F questionnaire was applied and considered high risk if score > 4. Muscle strength was assessed by handgrip strength (HS) using a manual dynamometer (Jamar®) . The muscle mass was assessed by electrical bioimpedance (BIA - Inbody®) obtaining the skeletal muscle mass index (SMI = MM appendicular / height2) . The physical performance was assessed by the timed up-and-go test (TUG) . The presence of sarcopenia was considered when HS <16Kg for women and <27Kg for men and confirmed when SMI <7.00 kg /m2 for men and ≤5.50 kg / m2 for women. The severity was evaluated when TUG was ≥20s.
Results: We assessed 125 patients aged 72.8 ± 5.8 y/o, 53% women and T2D median duration of 21 years (min 1; max 47) ; HbA1c=8.5 ± 1,5%. 50,5% of patients had macrovascular complications history; 25.8% retinopathy; 48,3% neuropathy and 14,3% nephropathy. 18,8% had SARC-F score > 4 indicating high risk of sarcopenia. However, the clinical tests confirmed sarcopenia in only 1,6% of the participants.
Conclusions: The prevalence of sarcopenia in older adults with T2D on insulin treatment was lower than general population, which may be explained by the insulin anabolic effects.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db22-805-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetic neuropathy ; Glucocorticoids ; Insulin ; Malignancy ; Muscle strength ; Nephropathy ; Older people ; Patients ; Retinopathy ; Sarcopenia ; Skeletal muscle</subject><ispartof>Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids></links><search><creatorcontrib>LEITE, SILMARA A.O.</creatorcontrib><creatorcontrib>BASTOS, MURILO</creatorcontrib><creatorcontrib>SILVA, MICHAEL</creatorcontrib><creatorcontrib>LAVALLE, ANA C.R.</creatorcontrib><creatorcontrib>BERTOGY, MARIA C.</creatorcontrib><creatorcontrib>VIEIRA, SUELEN C.</creatorcontrib><creatorcontrib>UMPIERREZ, GUILLERMO E.</creatorcontrib><title>805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes</title><title>Diabetes (New York, N.Y.)</title><description>Background: The relationship of sarcopenia with relevant features of T2D and its treatment are inconsistent in the literature.
Aims: To evaluate the prevalence of sarcopenia in insulin treated older adults with T2DM.
Methods: This is a cross sectional data from a prospective observational cohort study that evaluated subjects older than 65 y/o with T2D on insulin therapy, with or without oral agents, and HbA1c between 7% and 9%, identified from a public hospital and a private diabetes clinic and invited by phone to participate (n= 462) . Patients treated with GLP1 agonists; eGFR <30 ml/min; Hb <11g/dL; ALT> 3x ULN; glucocorticoid use in the previous 3 months, and active malignancy were excluded. The diagnosis of sarcopenia was based on the European Working Group on Sarcopenia in Older People (EWGSOP2) . The SARC-F questionnaire was applied and considered high risk if score > 4. Muscle strength was assessed by handgrip strength (HS) using a manual dynamometer (Jamar®) . The muscle mass was assessed by electrical bioimpedance (BIA - Inbody®) obtaining the skeletal muscle mass index (SMI = MM appendicular / height2) . The physical performance was assessed by the timed up-and-go test (TUG) . The presence of sarcopenia was considered when HS <16Kg for women and <27Kg for men and confirmed when SMI <7.00 kg /m2 for men and ≤5.50 kg / m2 for women. The severity was evaluated when TUG was ≥20s.
Results: We assessed 125 patients aged 72.8 ± 5.8 y/o, 53% women and T2D median duration of 21 years (min 1; max 47) ; HbA1c=8.5 ± 1,5%. 50,5% of patients had macrovascular complications history; 25.8% retinopathy; 48,3% neuropathy and 14,3% nephropathy. 18,8% had SARC-F score > 4 indicating high risk of sarcopenia. However, the clinical tests confirmed sarcopenia in only 1,6% of the participants.
Conclusions: The prevalence of sarcopenia in older adults with T2D on insulin treatment was lower than general population, which may be explained by the insulin anabolic effects.</description><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetic neuropathy</subject><subject>Glucocorticoids</subject><subject>Insulin</subject><subject>Malignancy</subject><subject>Muscle strength</subject><subject>Nephropathy</subject><subject>Older people</subject><subject>Patients</subject><subject>Retinopathy</subject><subject>Sarcopenia</subject><subject>Skeletal muscle</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNotkEtLxDAUhYMoOI5u_AUBd0I0jzZp3A3ja2BwCnbhLmSaG-xQ25qkyPx7O47cxdl8nMP9ELpm9I4Loe7dlnNS0JyUJ2jGtNBEcPVximaUMk6Y0uocXcS4o5TK6Wbo7Q9-wO821P0AXWNx0-FVF8e26UgVwCZweNM6CHjhxjbh0qYGuhTxT5M-cbUfAHP82NgtJIiX6MzbNsLVf85R9fxULV_JevOyWi7WpJaCEssoOMe34AvHlZOZdR4EWCmZ5szrPKu9K5TkmmuWSV9bxaUQ03O5AMeUmKObY-0Q-u8RYjK7fgzdtGi4LPJcZzKjE3V7pOrQxxjAmyE0XzbsDaPmoMscdJnJgCnFLzjBW3I</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>LEITE, SILMARA A.O.</creator><creator>BASTOS, MURILO</creator><creator>SILVA, MICHAEL</creator><creator>LAVALLE, ANA C.R.</creator><creator>BERTOGY, MARIA C.</creator><creator>VIEIRA, SUELEN C.</creator><creator>UMPIERREZ, GUILLERMO E.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20220601</creationdate><title>805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes</title><author>LEITE, SILMARA A.O. ; BASTOS, MURILO ; SILVA, MICHAEL ; LAVALLE, ANA C.R. ; BERTOGY, MARIA C. ; VIEIRA, SUELEN C. ; UMPIERREZ, GUILLERMO E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c630-a10edd2bef8d27d64adfe3ea661921f954cfd8762929146fca72633db253ed173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetic neuropathy</topic><topic>Glucocorticoids</topic><topic>Insulin</topic><topic>Malignancy</topic><topic>Muscle strength</topic><topic>Nephropathy</topic><topic>Older people</topic><topic>Patients</topic><topic>Retinopathy</topic><topic>Sarcopenia</topic><topic>Skeletal muscle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEITE, SILMARA A.O.</creatorcontrib><creatorcontrib>BASTOS, MURILO</creatorcontrib><creatorcontrib>SILVA, MICHAEL</creatorcontrib><creatorcontrib>LAVALLE, ANA C.R.</creatorcontrib><creatorcontrib>BERTOGY, MARIA C.</creatorcontrib><creatorcontrib>VIEIRA, SUELEN C.</creatorcontrib><creatorcontrib>UMPIERREZ, GUILLERMO E.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEITE, SILMARA A.O.</au><au>BASTOS, MURILO</au><au>SILVA, MICHAEL</au><au>LAVALLE, ANA C.R.</au><au>BERTOGY, MARIA C.</au><au>VIEIRA, SUELEN C.</au><au>UMPIERREZ, GUILLERMO E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2022-06-01</date><risdate>2022</risdate><volume>71</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Background: The relationship of sarcopenia with relevant features of T2D and its treatment are inconsistent in the literature.
Aims: To evaluate the prevalence of sarcopenia in insulin treated older adults with T2DM.
Methods: This is a cross sectional data from a prospective observational cohort study that evaluated subjects older than 65 y/o with T2D on insulin therapy, with or without oral agents, and HbA1c between 7% and 9%, identified from a public hospital and a private diabetes clinic and invited by phone to participate (n= 462) . Patients treated with GLP1 agonists; eGFR <30 ml/min; Hb <11g/dL; ALT> 3x ULN; glucocorticoid use in the previous 3 months, and active malignancy were excluded. The diagnosis of sarcopenia was based on the European Working Group on Sarcopenia in Older People (EWGSOP2) . The SARC-F questionnaire was applied and considered high risk if score > 4. Muscle strength was assessed by handgrip strength (HS) using a manual dynamometer (Jamar®) . The muscle mass was assessed by electrical bioimpedance (BIA - Inbody®) obtaining the skeletal muscle mass index (SMI = MM appendicular / height2) . The physical performance was assessed by the timed up-and-go test (TUG) . The presence of sarcopenia was considered when HS <16Kg for women and <27Kg for men and confirmed when SMI <7.00 kg /m2 for men and ≤5.50 kg / m2 for women. The severity was evaluated when TUG was ≥20s.
Results: We assessed 125 patients aged 72.8 ± 5.8 y/o, 53% women and T2D median duration of 21 years (min 1; max 47) ; HbA1c=8.5 ± 1,5%. 50,5% of patients had macrovascular complications history; 25.8% retinopathy; 48,3% neuropathy and 14,3% nephropathy. 18,8% had SARC-F score > 4 indicating high risk of sarcopenia. However, the clinical tests confirmed sarcopenia in only 1,6% of the participants.
Conclusions: The prevalence of sarcopenia in older adults with T2D on insulin treatment was lower than general population, which may be explained by the insulin anabolic effects.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db22-805-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2685594640 |
| source | PubMed Central; EZB Electronic Journals Library |
| subjects | Diabetes Diabetes mellitus (non-insulin dependent) Diabetic neuropathy Glucocorticoids Insulin Malignancy Muscle strength Nephropathy Older people Patients Retinopathy Sarcopenia Skeletal muscle |
| title | 805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T17%3A03%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=805-P:%20Sarcopenia%20in%20Insulin-Treated%20Older%20Adult%20Patients%20with%20Type%202%20Diabetes&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=LEITE,%20SILMARA%20A.O.&rft.date=2022-06-01&rft.volume=71&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db22-805-P&rft_dat=%3Cproquest_cross%3E2685594640%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685594640&rft_id=info:pmid/&rfr_iscdi=true |